RecruitingPhase 3NCT07052214

PSMA PET Combined With MRI for the Detection of PCa

Studying Posterior cortical atrophy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Intervention: 68Ga-PSMA-11(drug)
Enrollment: 204 target
Eligibility: 18 years · MALE
Timeline: 2025 – 2026

Study locations (1)

Australian Prostate Centre, Melbourne N., Victoria, Australia

Collaborators

Telix Innovations S.A.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07052214 on ClinicalTrials.gov

Other trials for Posterior cortical atrophy

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT07191327
Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy
University of Michigan
RECRUITINGNANCT06820190
Analgesic Efficacy of Multiple Mid-Transverse Process to Pleura (MTP) Block and PCA in Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion
Tanta University
RECRUITINGNANCT07051109
Dual-chamber Patient-controlled Analgesia for Postoperative Recovery
Seoul National University Bundang Hospital
ACTIVE NOT RECRUITINGNANCT02740634
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Mayo Clinic

See all trials for Posterior cortical atrophy →

← Back to all trials